← Russell 3000 cross-section

MDXG MIMEDX GROUP, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$676m
Revenue TTM
$355m
Net income TTM
$6m
Free cash flow
Composite score
44.6
Sector rank
#2247

Valuation

P / E
108.4
EV / EBITDA
47.6
EV / sales
1.6
FCF yield
Earnings yield vs 10-yr
-3.81pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.8%
EBITDA margin
3.3%
ROE
2.9%
ROIC
9.1%
Revenue growth
-2.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

These efforts contributed to continued growth in the Surgical business, which demonstrated a sixth consecutive quarter of double-digit year-over-year growth. • Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales. Results of Operations Three Months Ended June 30, 2026 Compared to the Three Months Ended June 30, 2025 Changes noted as “nm” in the table above indicate that the percentage change is not meaningful. …MIMEDX GROUP, INC., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →